European Pharmaceutical Review

NOVEMBER 19, 2024

.” In a Q&A with EPR last year, Hoppin and Ratio’s Director, President and Chief Scientific Officer, Dr John Babich, described that “there is great hope of this class of drug specifically to work in conjunction with immunotherapeutics, given the lack of toxicity of radiopharmaceuticals in general compared to most chemotherapies.”

Chemotherapy 52

Chemotherapy FDA 52

Pharmacy Times

JUNE 6, 2025

According to the study authors, it represents the sixth leading cause of cancer-related mortality in the US and was the fourth most commonly diagnosed cancer worldwide in 2022. 1 Image credit: sinhyu | stock.adobe.com HCC is the most prevalent type of primary liver cancer in adults.

Compounding Pharmacies 65

Compounding Pharmacies Immunization Chemotherapy Compounding 65

pharmaphorum

JULY 18, 2025

Skip to main content Friday 18 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Chemotherapy Compounding 52

European Pharmaceutical Review

MAY 3, 2023

The blood-brain barrier (BBB) in glioblastoma patients was opened temporarily using a novel, skull-implantable ultrasound device to deliver chemotherapy to the brain in a first in-human trial. Two chemotherapy drugs , paclitaxel and carboplatin were injected intravenously during the four-minute procedure.

Chemotherapy 119

Chemotherapy 119

IDStewardship

DECEMBER 26, 2022

In this article we do a quick run down on IDstewardship for the end of 2022. . Article Posted 26 December 2022. 2022 has come and gone in what seems like a flash. TOP 3 NEW ARTICLES FROM 2022. EDITOR’S CHOICE: BEST ARTICLE OF 2022. Thank you to all of the contributors, collaborators, and interviewees in 2022!

Chemotherapy 130

Chemotherapy Hospitals 130

European Pharmaceutical Review

OCTOBER 27, 2022

Could the new wave of taxane chemotherapies succeed where traditional chemotherapies have failed? The post Drug Formulation In-Depth Focus 2022 appeared first on European Pharmaceutical Review. Solving the taxing problems of taxanes?

Chemotherapy 98

Chemotherapy Dosage 98

STAT

NOVEMBER 30, 2023

Central to the deal, expected to close in the middle of next year, is Elahere, an Immunogen product that won Food and Drug Administration approval for advanced ovarian cancer in 2022.

Chemotherapy 142

Chemotherapy 142

pharmaphorum

NOVEMBER 28, 2021

The three-year phase 2 trial will be carried out by researchers at Leeds University led by professor of clinical oncology and neuro-oncology Susan Short, and see if adding Sativex (nabiximols) to standard chemotherapy for recurrent glioblastoma can extend survival. Jazz acquired rights to Sativex when it completed its $7.2

Chemotherapy 136

Chemotherapy FDA Hospitals 136

Pharmaceutical Technology

SEPTEMBER 13, 2022

Once patients become resistant to standard of care (SOC) endocrine-based therapies and CDK 4/6 inhibitors, the prognosis is poor, with treatment options limited to single-agent chemotherapies. Findings of the study, reported at the ESMO Congress 2022, demonstrated a 3.2-month months) versus physicians’ choice chemotherapy (11.2

Chemotherapy 64

Chemotherapy FDA 64

Pharmaceutical Technology

MARCH 30, 2023

The European Commission (EC) has granted approval for Regeneron Pharmaceuticals’ Libtayo (cemiplimab), along with platinum-based chemotherapy, as the first-line treatment for PD-L1 expression positive advanced non-small cell lung cancer (NSCLC) in adult patients.

Chemotherapy 52

Chemotherapy Immunization FDA 52

The Guardian - Pharmaceutical Industry

JANUARY 5, 2024

Pedro, five, was diagnosed with neuroblastoma; a fund has been set up so that his family can afford expensive chemotherapy drug Leading artists, Indigenous activists and politicians across Brazil are urging people to contribute to a fund to help the son of the slain Amazon activist Bruno Pereira , who has been diagnosed with a rare form of cancer.

Chemotherapy 108

Chemotherapy 108

European Pharmaceutical Review

MARCH 21, 2023

This data led to the US approval for initial treatment of R/R LBCL in April 2022 and European Union approval in October 2022. Historical SOC involves platinum-based salvage combination chemoimmunotherapy regimen followed by high-dose therapy (HDT) and stem cell transplant (ASCT) in patients who respond to salvage chemotherapy.

Chemotherapy 145

Chemotherapy 145

Pharmaceutical Technology

SEPTEMBER 13, 2022

Presentations at the ESMO Congress 2022 have demonstrated the critical importance of therapy sequence, with astounding results for neoadjuvant ICI use in melanoma and microsatellite instability-high or mismatch repair deficient (MSI-H/dMMR) colorectal cancer (CRC). month progression-free survival (PFS) benefit over SOC chemotherapy.

Chemotherapy 69

Chemotherapy Immunization 69

STAT

JULY 19, 2023

The first time, her physicians flipped the order of her drug regimen because Taxol (paclitaxel), one of two drugs she was supposed to take, was not available, said McInerney, who was diagnosed in December 2022. Read the rest…

Chemotherapy 98

Chemotherapy 98

STAT

AUGUST 9, 2023

Nearly 10 years ago, up to 83% of oncologists surveyed could not prescribe a preferred chemotherapy agent due to shortages. At the end of 2022, there were national shortages of 295 medications , including essentials like anesthetics, chemotherapies, and antibiotics. Continue to STAT+ to read the full story…

Chemotherapy 98

Chemotherapy 98

European Pharmaceutical Review

DECEMBER 7, 2022

In addition, A Phase III trial of Ivonescimab plus chemotherapy versus chemotherapy in epidermal growth factor receptor (EGFR) mutated advanced non-squamous NSCLC that failed in prior epidermal growth factor receptor EGFR tyrosine kinase inhibitors (TKIs) therapy is ongoing. percent and a median progression-free survival (mPFS) of 8.2

Chemotherapy 98

Chemotherapy 98

European Pharmaceutical Review

DECEMBER 12, 2024

This authorisation of the antibody drug conjugate Elahere provides a much needed clinically meaningful option for women living with this type of ovarian cancer, whose disease returns because they develop resistance to platinum-based chemotherapy regimens. Plymouth Meeting, PA: National Comprehensive Cancer Network 2022. 2022; 32(6).

Chemotherapy 98

Chemotherapy 98

STAT

NOVEMBER 30, 2023

Food and Drug Administration approval for advanced ovarian cancer in 2022. Elahere is among a surging class of cancer medicines called antibody-drug conjugates, or ADCs, which are designed to deliver a targeted dose of chemotherapy directly to tumor cells while sparing healthy tissues.

Compounding 109

Compounding Compounding Pharmacies Chemotherapy FDA 109

European Pharmaceutical Review

AUGUST 12, 2022

The highest ORR was observed in patients with high levels of MET who were not treated with prior chemotherapy (52 percent). The results were shared at the International Association for the Study of Lung Cancer 2022 World Conference on Lung Cancer in Vienna, Austria.

Chemotherapy 98

Chemotherapy 98

pharmaphorum

JANUARY 26, 2023

Yescarta is administered to the patient via a single intravenous infusion following the administration of a round of chemotherapy designed to accommodate the new cells and minimise the patient’s immune reaction to them. About 50% will ultimately relapse post-transplant.

Chemotherapy 96

Chemotherapy Immunization Hospitals 96

European Pharmaceutical Review

NOVEMBER 6, 2023

In addition to being indicated in those with progressive disease, Mirati Therapeutics shared that the treatment is also authorised for patients with, or intolerance to, platinum-based chemotherapy and/or anti-PD-1/PD-L1 immunotherapy.

Chemotherapy 98

Chemotherapy Hospitals 98

pharmaphorum

APRIL 19, 2022

The review will mainly look at AZ and Daiichi Sankyo’s DESTINY-Lung01, a phase 2 trial which showed a 55% overall response rate for Enhertu in patients previously treated with platinum chemotherapy, mainly partial responses, with a median duration of response of just over 9 months.

FDA 105

FDA Chemotherapy 105

European Pharmaceutical Review

MAY 4, 2023

Amivantamab was the first bispecific monoclonal antibody (BsMAb) approved in the EU to treat advanced NSCLC with EGFR exon 20 insertion mutations post chemotherapy. 2022; 10(1). 2022; 24(2): 89 – 97. New bispecific antibody generation platforms were identified as one of the major drivers of the market in the next few years.

Immunization 98

Immunization Chemotherapy FDA 98

European Pharmaceutical Review

JULY 12, 2022

The transaction is expected to close in the third quarter of 2022, subject to customary closing conditions and regulatory clearances. AstraZeneca’s blood-cancer treatment portfolio already includes Calquence (acalabrutinib), a chemotherapy-free monotherapy for patients with chronic lymphocytic leukaemia (CLL). .

Immunization 98

Immunization Chemotherapy 98

Pharmaceutical Technology

MAY 10, 2023

The approval was given to TYVYT (sintilimab injection) plus bevacizumab and chemotherapy (pemetrexed and cisplatin). Major secondary endpoints of objective response rate and duration of response were also found to be improved when patients were treated with sintilimab plus bevacizumab plus chemotherapy, in comparison with chemotherapy alone.

Chemotherapy 52

Chemotherapy 52

pharmaphorum

SEPTEMBER 11, 2022

The patient then receives chemotherapy to reduce regulatory T cells that can put a brake on immune responses to tumours, as well as immune-boosting cytokine interleukin-2, before the TILs are then reinfused into the patient intravenously. .

Chemotherapy 105

Chemotherapy Immunization Hospitals 105

pharmaphorum

NOVEMBER 18, 2022

The PhALLCON trial compared Iclusig (ponatinib) to imatinib – sold by Novartis as Glivec/Gleevec, but also available as a generic – on top of a reduced-intensity chemotherapy regimen in 230 patients with this type of leukaemia. Takeda booked 23.2

Chemotherapy 98

Chemotherapy 98

European Pharmaceutical Review

DECEMBER 6, 2022

Most manufacturers were successful in their AAP application, with the HAS acknowledging most products met all three major criteria” In the first seven months since this reform, July 2021 to February 2022, 17 new product applications were submitted for an autorisation d’accès précoce (AAP, which includes the previous cohort ATU).

Chemotherapy 98

Chemotherapy 98

Pharmaceutical Technology

JUNE 4, 2023

Patients with resectable stage II, IIIA, and IIIB (T3-4N2) disease of both squamous and non-squamous histology were randomized to receive neoadjuvant Keytruda with platinum-based chemotherapy followed by adjuvant Keytruda, or placebo with platinum-based chemotherapy followed by placebo. At a median duration of follow-up of 25.2

Chemotherapy 75

Chemotherapy Hospitals FDA 75

Pharmaceutical Technology

MARCH 30, 2023

On March 27, MSD announced that the combined use of Keytruda with chemotherapy significantly improved progression-free survival versus the chemotherapy alone, as a first-line therapy for advanced or recurrent endometrial carcinoma. In 2022, the company reported Keytuda sales of $20.9 billion in its FY 2022 results.

Chemotherapy 52

Chemotherapy Packaging Documentation FDA 52

pharmaphorum

JUNE 18, 2021

ADC called mirvetuximab soravtansine in phase 3 testing for platinum-resistant ovarian cancer that could start generating results before the end of the year – setting up a potential approval in 2022. Another rival is Sutro Biopharma, whose STRO-002 ADC candidate – partnered with Merck KGaA – has just started phase 1 testing.

Chemotherapy 98

Chemotherapy 98

Pharmaceutical Technology

MAY 11, 2023

Along with azacytidine, the therapy is indicated to treat newly diagnosed IDH1 R132-mutated AML adult patients who are not eligible to receive standard induction chemotherapy. It is claimed to be the first and only IDH1-targeted therapy to receive approval in Europe.

Chemotherapy 52

Chemotherapy 52

European Pharmaceutical Review

DECEMBER 12, 2022

Without the experimental CD7 CAR-T cell therapy, having previously undergone unsuccessful conventional treatments including chemotherapy and a bone marrow transplant, the patient’s only other option was palliative care. The positive data was presented for the first time at the 2022 American Society of Haematology (ASH) annual meeting.

Chemotherapy 124

Chemotherapy Hospitals 124

Pharmaceutical Technology

MARCH 6, 2023

Patients in the US and EU with recurrent or metastatic nasopharyngeal carcinoma (NPC), a subtype of head and neck squamous cell carcinoma (HNSCC), are mostly treated with a combination of chemotherapy agents in the frontline setting, such as cisplatin + gemcitabine. months for the chemotherapy arm (hazard ratio [HR]: 0.52).

Chemotherapy 52

Chemotherapy FDA Labelling Immunization 52

pharmaphorum

DECEMBER 5, 2022

Pluvicto becomes the first PSMA-targeted intravenous radioligand therapy – combining a targeting compound or ligand with a therapeutic radionuclide or radioactive particle (in this case, lutetium-177) – to demonstrate clinical benefit in mCRPC patients before receiving taxane-based chemotherapy.

Chemotherapy 59

Chemotherapy Compounding Labelling FDA 59

Pharmaceutical Technology

FEBRUARY 26, 2023

In November 2022, Ferring Pharmaceuticals’s Rebyota became the first FDA-approved microbiome-based therapeutic to treat recurrent CDI. On February 16, the microbiome therapeutics-focused biotech 4D Pharma was pulled from the London Stock Exchange after falling into administration in June 2022.

FDA 111

FDA Immunization Chemotherapy 111

Pharmaceutical Technology

MARCH 23, 2023

The drug is currently licensed in combination with chemotherapy for patients with classical Hodgkin lymphoma, both as frontline therapy and for those at risk of progressing or having progressed following stem cell transplantation. Seagen generated almost $2 billion in revenue in 2022, an increase approaching 25% from 2021.

Chemotherapy 59

Chemotherapy Compounding FDA 59